Probiotec (PBP) - Ceasing Coverage
We have decided to cease coverage of PBP in order to reallocate our resources.
Please login to read the full article
Probiotec (PBP) - Long Road Back
Very disappointing FY11 NPAT guidance (-45% on FY10) sees our EPS estimates & valuation halve.
Please login to read the full article
Probiotec (PBP) - A Weighting Game For Now
Probiotec issued a low quality FY10 result.
Please login to read the full article
Probiotec (PBP) - Earnings Trimmed
Weaker domestic sales, FX headwinds (€/£), brand acquisition & legal settlements drive 11-12% EPS downgrades.
Please login to read the full article
Probiotec (PBP) - Risk Profile Goes Up
Low quality result & increased competition in the domestic market drive 8-13% EPS downgrades in FY11-12.
Please login to read the full article